Sugi Predict

Sugi Predict / Compounds / SCHEMBL180505

SCHEMBL180505

SCHEMBL180505

CC(C)(C)OC(=O)N1CCC(c2ccc(Br)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.60
▸ GPR119 Q8TDV5 5/20 0.54
▸ FPR2 P25090 4/20 0.54
▸ KDM4E B2RXH2 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ THRB P10828 1/20 0.53
▸ RORC P51449 2/20 0.51
▸ DDB1 Q16531 1/20 0.51
▸ CRBN Q96SW2 1/20 0.51
▸ PTPN2 P17706 1/20 0.50
▸ PTPN1 P18031 1/20 0.50
▸ PTPN6 P29350 1/20 0.50
▸ PDE4B Q07343 1/20 0.49
▸ FPR3 P25089 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dioxane SCHEMBL28861455 0.94 USP2 (0.55) NAMPTGPR119FPR2KDM4EMAPT
SCHEMBL1015283 0.92 PDE4B (0.58) NAMPTGPR119FPR2KDM4EMAPT
SCHEMBL1015281 0.92 PDE4B (0.58) NAMPTGPR119FPR2KDM4EMAPT
SCHEMBL28861456 0.91 NAMPT (0.53) NAMPTGPR119FPR2KDM4EMAPT
SCHEMBL31222940 0.88 FPR2 (0.49) NAMPTGPR119FPR2KDM4EMAPT
SCHEMBL3854559 0.87 NAMPT (0.61) NAMPTGPR119KDM4EMAPTTHRB
SCHEMBL12117456 0.87 GPR119 (0.65) NAMPTGPR119KDM4EMAPTTHRB
SCHEMBL31274808 0.86 NAMPT (0.48) NAMPTGPR119FPR2KDM4EMAPT
SCHEMBL2594236 0.86 NAMPT (0.60) NAMPTGPR119KDM4EMAPTTHRB
SCHEMBL270733 0.86 NAMPT (0.60) NAMPTGPR119KDM4EMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624044-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-05-12 — — US disclosed
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEONE MEDICINES I GMBH (CH) 2026-04-28 — — US disclosed
US-20260109708-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE CELGENE CORP (US) 2026-04-23 — — US disclosed
EP-4722208-A1 NOVEL BENZAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Samjin Pharmaceutical Co., Ltd. (KR) 2026-04-08 — — EP disclosed
US-20260015338-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 — — US disclosed
EP-4676476-A1 INHIBITORS OF TDP-43 AND TAU AGGREGATION Aquinnah Pharmaceuticals, Inc. (US) 2026-01-14 — — EP disclosed
WO-2025262297-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2025-12-26 — — WO disclosed
EP-4667467-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 Dark Blue Therapeutics Ltd (GB) 2025-12-24 — — EP disclosed
EP-4663628-A1 NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Samjin Pharmaceutical Co., Ltd. (KR) 2025-12-17 — — EP disclosed
EP-4661875-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE Celgene Corporation (US) 2025-12-17 — — EP disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 — — US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 — — US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 — — US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 — — US disclosed
WO-2007070398-A1 POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS SCHERING CORPORATION (US) 2007-06-21 — — WO disclosed
WO-2007056075-A2 SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 — — WO disclosed
WO-2007056075-A2 SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 — — WO disclosed
US-20060252768-A1 2,3,6-Trisubstituted-4-pyrimidone derivatives SANOFI (FR) 2006-11-09 — — US disclosed
EP-1608630-A1 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2005-12-28 — — EP disclosed
WO-2004085408-A1 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES MITSUBISHI PHARMA CORPORATION (JP) 2004-10-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015338-A1 TARGETED PROTEIN DEGRADATION PSMC3, PSMA6, ADRM1 NAMPT 4868/4885GPR119 4055/4885FPR2 3451/4885
US-20070191604-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 NAMPT 1820/4885GPR119 1990/4885FPR2 3660/4885
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR8, TLR1 NAMPT 3299/4885GPR119 180/4885FPR2 339/4885
US-12624044-B2 SMARCA degraders and uses thereof SMARCA1, SMARCC1, SMARCA2 NAMPT 4562/4885GPR119 3736/4885FPR2 4451/4885
US-20060252768-A1 2,3,6-Trisubstituted-4-pyrimidone derivatives PSEN1, PSEN2, MAPT NAMPT 2134/4885GPR119 1133/4885FPR2 3254/4885
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations ABL1, KDR, BCR NAMPT 2364/4885GPR119 2201/4885FPR2 4355/4885
US-20260109708-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE PSME2, MKRN3, RPS6KA2 NAMPT 3018/4885GPR119 3349/4885FPR2 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.